Brief: Viva Biotech's Portfolio Company DTX Pharma Says Reached Acquisition Agreement With Novartis

VIVA Biotech Holdings

18/07/2023 08:07

July 18 (Reuters) - Viva Biotech  1873.HK :
    * Viva Biotech's PORTFOLIO COMPANY DTX PHARMA REACHED THE
ACQUISITION AGREEMENT WITH NOVARTIS
    * NOVARTIS WILL MAKE AN UPFRONT PAYMENT OF $500M AND
ADDITIONAL
PAYMENTS OF UP TO $500M UPON COMPLETION OF PRE-SPECIFIED
MILESTONES
    * ACQUISITION ALSO INCLUDES ADDITIONAL EARLY-STAGE PROGRAMS
IN
NEUROMUSCULAR AND CNS INDICATIONS
    * NOVARTIS WILL MAKE AN UPFRONT PAYMENT OF $500M AND
ADDITIONAL
PAYMENTS OF UP TO $500M UPON COMPLETION OF PRE-SPECIFIED
MILESTONES
    * ACQUISITION INCLUDES DTX-1252 WITH POTENTIAL TO DELIVER A
TRANSFORMATIVE MEDICINE TO CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
(CMT1A) PATIENTS

Source text for Eikon:  ID:nPn10HVRFa 
Further company coverage:  1873.HK 

 ((Reuters.Briefs@thomsonreuters.com;))